01- ISCHEMIA: Prognosis is Determined by Anatomy, not Functionality The ISCHEMIA study keeps providing scientific news. This work in patients with stable coronary artery disease had already shown (to our surprise) that ischemic burden does not predict 4-year mortality. Read also HERE 02- Chile Sessions 2021 | Clinical Case Contest for Young Interventionists It is with great<a href="https://solaci.org/en/2021/11/05/the-most-read-articles-in-interventional-cardiology-in-october/" title="Read more" >...</a>
AFIRE Trial: Atrial Fibrillation and PCI. What is the Ideal Therapy?
Patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) will benefit from rivaroxaban monotherapy both in terms of safety and efficacy. The AFIRE study included 2215 patients with atrial fibrillation and stable coronary artery disease (CAD). A subgroups analysis recently published in JACC Intv evaluated patients undergoing coronary stenting. The study compared rivaroxaban + antiplatelet<a href="https://solaci.org/en/2021/11/04/afire-trial-atrial-fibrillation-and-pci-what-is-the-ideal-therapy/" title="Read more" >...</a>
10 Years Treating Bifurcations: Have We Made Progress?
Bifurcations have been, are and will be challenging. However, we have to admit we have gained experience and have more tools than pioneer interventionists and many of the early experts who have made history. This study assessed the ten-year trends in coronary bifurcation percutaneous coronary intervention (PCI) looking at patient and lesion characteristics, devices used,<a href="https://solaci.org/en/2021/10/26/10-years-treating-bifurcations-have-we-made-progress/" title="Read more" >...</a>
Drug-Eluting Balloons Find Their Niche
According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat in-stent restenosis. Drug-eluting balloons seem to work equally well for the treatment of long-term in-stent restenosis compared with new stent implantation (for the thin-strut DES registry). If DEBs can compete with DES—adding to the advantage of avoiding a<a href="https://solaci.org/en/2021/10/13/drug-eluting-balloons-find-their-niche/" title="Read more" >...</a>
Watch Again Advanced Strategias on Bifurcations Management in our Youtube Account
Watch Again “Advanced Strategias on Bifurcations Management” in our Youtube Account Program Provisional stent technique as a treatment philosophy: the step by step and when to use it. Critical analysis of the POT, Kissing, Re POT technique. Provisional strategy vs 2 stents in No ULM The case in which I require a second stent: when,<a href="https://solaci.org/en/2021/10/05/watch-again-advanced-strategias-on-bifurcations-management-in-our-youtube-account/" title="Read more" >...</a>
The most read scientific papers of September in interventional cardiology
01- ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European<a href="https://solaci.org/en/2021/10/01/the-most-read-scientific-papers-of-september-in-interventional-cardiology/" title="Read more" >...</a>
XIENCE SHORT DAPT | Ideal DAPT Period for Patients at High Risk of Bleeding
In patients at high risk of bleeding undergoing coronary stenting with a Xience stent, 1-to-3-month DAPT period resulted non-inferior to a 6-to-12-month period in terms of ischemic events, and this could be associated to a lower rate of major bleeding and lower stent thrombosis incidence. There is no longer an indication for conventional stents in<a href="https://solaci.org/en/2021/09/27/xience-short-dapt-ideal-dapt-period-for-patients-at-high-risk-of-bleeding/" title="Read more" >...</a>
SOLACI-CACI 2021 | CBS Session
✔️ Watch again the CBS Session in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 00:01 – Live case from Nanjing First Hospital, NMU, Nanjing, China – Operators: Shao-Liang Chen, Jun-Jie Zhang / IVUS interpreter: Tao Pan 👉🏻 Panelists: Costa, Ricardo – Cura, Fernando – Londero, Hugo – Samaja, Gustavo – Sheiban, Imaid – Rab, Tanveer S.<a href="https://solaci.org/en/2021/09/14/solaci-caci-2021-cbs-session/" title="Read more" >...</a>
SOLACI-CACI 2021 | EuroPCR Session
✔️ Watch the complete PCR in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 👉 How to manage Coronary Artery Disease in patients with Severe Aortic Stenosis eligible for TAVI? 04:51 – How does Coronary Artery Disease impact decision-making process of the Heart Team for patients with symptomatic severe AS? – Round Table Discussion 10:59 – ACTIVATION<a href="https://solaci.org/en/2021/09/14/solaci-caci-2021-europcr-session/" title="Read more" >...</a>
SOLACI-CACI 2021 | Current CONTROVERSIES in INTERVENTIONAL CARDIOLOGY – Medtronic Symposium
✔️ MEDTRONIC Symposium in the SOLACI-CACI 2021 Virtual Congress.✔️ Topic: Current Controversies in Interventional Cardiology. 👨‍🏫 Program: Opening – Dr. Aníbal Damonte. Controversy in Bifurcation Lesions: Which Strategy is Adequate When Implanting Two Stents Is Possible? DK Crush as an Option – Dr. Carlos Uribe. Provisional Stenting as an Option – Dr. Ricardo Costa<a href="https://solaci.org/en/2021/09/13/solaci-caci-2021-current-controversies-in-interventional-cardiology-medtronic-symposium/" title="Read more" >...</a>